March 13th 2023
Shilpa Gupta, MD, discusses bladder preserving strategies for unfit or young patients, trials assessing immunotherapy combinations, and results from the BLASST-1 trial presented at ASCO GU.
February 20th 2023
February 18th 2023
Metastatic Urothelial Carcinoma: Discussing Maintenance Therapy With PatientsJanuary 3rd 2022
Shared insight on how best to discuss maintenance therapy with patients being treated for metastatic urothelial carcinoma.
When to Use Maintenance Therapy in Metastatic Urothelial CarcinomaJanuary 3rd 2022
Panelists consider whether the use of maintenance therapy is as prevalent after complete response or in patients with lesser PD-L1 expression.
Metastatic Urothelial Carcinoma: Experience With Maintenance AvelumabDecember 21st 2021
Experts highlight the benefits of frontline avelumab maintenance therapy in patients with metastatic urothelial carcinoma.
Metastatic Urothelial Carcinoma: Optimizing Frontline Maintenance TherapyDecember 10th 2021
Shared insight on best practices in frontline maintenance therapy for metastatic urothelial carcinoma to improve patient outcomes.
Selecting Frontline Therapy for Metastatic Urothelial CarcinomaDecember 10th 2021
Reviewing a patient case of metastatic urothelial carcinoma, experts discuss the selection of frontline and maintenance therapy.
Post-Radical Cystectomy HRQOL Questionnaire Showed Favorable Recovery in Almost all Areas in Bladder CancerDecember 1st 2021
Patients with bladder cancer reported improvements in physical and social scores following radical cystectomy, although body image and sexual functioning scores decreased.
Daniel P. Petrylak, MD, Details Data From TROPHY U-01 Study in Previously Treated Metastatic Urothelial CarcinomaNovember 2nd 2021
Daniel P. Petrylak, MD, spoke with CancerNetwork® about the results of the TROPHY U-01 study examining sacituzumab govitecan in the treatment of patients with metastatic urothelial carcinoma following failure of platinum-based chemotherapy.
Increased Antibody Titers May Predict Durability of Nadofaragene Firadenovec in BCG-Unresponsive Non–Muscle Invasive Bladder CancerOctober 24th 2021
In patients with bacillus Calmette-Guérun–unresponsive non-muscle invasive bladder cancer who are being treated with nadofaragene firadenovec, elevated levels of antibody titers may be able to predict efficacy.
Intravesical BCG Plus Novel IL-15 Superagonist Complex Improves DFS in BCG-Unresponsive Non-Muscle Invasive Bladder CancerOctober 20th 2021
Patients with Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer experienced a disease-free survival benefit when treated with intravesical Bacillus Calmette-Guerin and a novel IL-15 superagonist complex .
Promising Safety and Activity Observed with Durvalumab/Vicineum in High-Grade NMIBCOctober 11th 2021
Patients with Bacillus-Calmette Guérin–unresponsive non–muscle invasive bladder cancer experienced promising responses to treatment with of durvalumab and Vicineum, which was also well tolerated.
Neoadjuvant Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab Provides Safe and Successful Downstaging Strategy for Muscle-Invasive Bladder CancerOctober 1st 2021
Patients with muscle-invasive bladder cancer treated with gemcitabine and split-dose cisplatin plus pembrolizumab experienced improved pathological downstaging.
FDA Approves Adjuvant Nivolumab for the Treatment of Patients With High-Risk Urothelial CarcinomaAugust 20th 2021
The FDA has approved nivolumab for patients with high-risk urothelial carcinoma regardless of previous treatment with neoadjuvant chemotherapy, nodal involvement, or PD-L1 status.
Adjuvant Nivolumab Demonstrates Improved Disease-Free Survival Over Placebo in Muscle Invasive Urothelial CarcinomaJuly 29th 2021
Patients with muscle invasive urothelial carcinoma who received adjuvant nivolumab experienced a longer disease-free survival compared with those who received placebo.
Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future OutlookJuly 15th 2021
Until 5 years ago, systemic therapeutic options for urothelial carcinoma, the most common form of bladder cancer, had been limited to cisplatin-based regimens and taxanes. This article explores the current and future outlooks for combination therapy with IOs in urothelial carcinoma.
Matthew D. Galsky, MD, on Key Takeaways From 2021 ASCO Annual Meeting in Bladder CancerJune 9th 2021
CancerNetwork® sat down with Matthew D. Galsky, MD, at the 2021 ASCO Annual Meeting to discuss his thoughts on research he believes has the greatest potential to impact standard of care treatment of bladder cancer.
Matthew D. Galsky, MD, Discussed Multidisciplinary Care for Treating MIBC With TURBT and Nivolumab ComboJune 7th 2021
CancerNetwork® sat down with Matthew D. Galsky, MD, at the 2021 ASCO Annual Meeting to talk about data from a phase 2 trial examining the use of neoadjuvant nivolumab plus gemcitabine/cisplatin prior to bladder-sparing surgery.
OS Analyses by Patient Subgroup Support Frontline Avelumab Maintenance in Advanced Urothelial CancerJune 4th 2021
Regardless of primary tumor site or disease stage, avelumab maintenance was able to elicit overall survival benefit versus best supportive care for platinum-treated urothelial cancer.